PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells

Blood Cancer Journal

Volumn 6, Issue , 2016, Pages e377-

  Glodkowska Mrowka, E ^a   Manda Handzlik, A ^a   Stelmaszczyk Emmel, A ^a   Seferynska, I ^b   Stoklosa, T ^a   Przybylski, J ^a   Mrowka, P ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CIGLITAZONE; DASATINIB; NILOTINIB; OCTAMER TRANSCRIPTION FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ROSIGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CARDIOVASCULAR RISK; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; HUMAN; K562 CELL LINE; NOTE; STEM CELL; WESTERN BLOTTING; AGONISTS; CANCER STEM CELL; DRUG EFFECTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PIPERAZINES; PPAR GAMMA; PYRIMIDINES; THIAZOLIDINEDIONES;

EID: 84953896874     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.109     Document Type: Note

References (8)

1. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
2. Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2015; 29: 586-597.
3. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144-4157.
4. Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 2015; 525: 380-383.
5. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014; 124: 511-518.
6. Glodkowska-Mrowka E, Mrowka P, Basak GW, Niesiobedzka-Krezel J, Seferynska I, Wlodarski PK et al. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Exp Hematol 2014; 42: 439-447.
7. Kim D, Alfraih F, Lee H, Lipton J. The Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy. Blood 2014; 124: 1804.
8. Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL et al. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 2014; 168: 823-9 e6.